Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Schrodinger Q3 2026 Results: Net Loss of $37.7M, Loss Widens

Schrodinger, Inc. reported its third quarter 2026 results, highlighting a history of operating losses and expectations for continued losses as it invests in its computational platform and proprietary drug discovery programs. The company is focused on leveraging its agentic AI co-scientist and strategic collaborations, such as with Novartis, to drive software growth and clinical advancement.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue64.554.3
Gross profit38.328.0
Profit before tax-37.6-32.6
Net income-37.7-32.8
EPS (diluted, $ a share)$-0.50$-0.45

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+18.7%
Gross margin59.3%
Operating margin-40.5%
Source

10-Q filed with the SEC, NASDAQ: SDGR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Schrodinger, Inc.: key numbers

Share price
$27.36Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Schrodinger, Inc.

All →
4:50 PM ET Form 4
Insider Selling

Schrodinger Insider Robert Lorne Abel Sells $803K of Stock

Robert Lorne Abel sold 23,605 shares of Schrodinger, Inc. at $34.00 a share, worth $803K in total on Nov 11, 2026. Shares held after the trade: 54,219 (-3.0%).

Value
$803K
Shares
23,605
Average price
$34.00
Holding change
-3.0%
Trade date
Nov 11, 2026
4:16 PM ET Form 4
Insider Selling

Schrodinger EVP, CLO & Cpo Yvonne Tran Sells $1.05M of Stock

Yvonne Tran, EVP, CLO & Cpo, sold 32,000 shares of Schrodinger, Inc. at $29.97 to $33.11 a share (average $32.85) in 4 transactions, worth $1.05M in total on Nov 9, 2026. Shares held after the trade: 52,683 (-29.1%).

Value
$1.05M
Shares
32,000
Average price
$32.85
Role
EVP, CLO & Cpo
Holding change
-29.1%
Trade date
Nov 9, 2026
4:08 PM ET 8-K
Financial Results

Schrodinger Financial Results

Schrodinger reported Q3 2026 financial results with total revenue of $64.5 million, a 19% increase year-over-year, driven by 17% growth in Annual Contract Value (ACV). The company raised its full-year 2026 guidance for both ACV and drug discovery revenue following strong software performance and a milestone payment from Structure Therapeutics.

Term
Q3 2026

“We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each other.”

Ramy Farid, Ph.D., chief executive officer of Schrödinger
5:15 PM ET Form 4
Insider Selling

Schrodinger Insider Karen Akinsanya Sells $928K of Stock

Karen Akinsanya sold 31,599 shares of Schrodinger, Inc. at $28.00 to $30.00 a share (average $29.37) in 2 transactions, worth $928K in total on Sep 17, 2026. Shares held after the trade: 69,956 (-23.6%).

Value
$928K
Shares
31,599
Average price
$29.37
Holding change
-23.6%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.